NCT04153175View on ClinicalTrials.gov

Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 21, 2020

Primary Completion Date

March 1, 2024

Study Completion Date

March 1, 2024

Conditions
Refractory Epilepsy
Interventions
COMBINATION_PRODUCT

ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)

Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of CT-010.

COMBINATION_PRODUCT

Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)

Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of a placebo (saline).

Trial Locations (11)

64239

Tel Aviv Sourasky Medical Center, Tel Aviv

Unknown

Mater Hospital Brisbane, Brisbane

RBWH, Brisbane

Royal Brisbane Medical Center, Brisbane

The Mater, Brisbane

SVHM, Melbourne

The Alfred, Melbourne

The Austin, Melbourne

Hadassah Medical Center, Jerusalem

Sheba Medical Center, Ramat Gan

Tel Aviv Sourasky Medical Center, Tel Aviv

Sponsors
All Listed Sponsors
lead

Cerebral Therapeutics LLC

INDUSTRY

NCT04153175 - Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization | Biotech Hunter | Biotech Hunter